Desoximetasone Cream USP, 0.25%

Cadila Healthcare Ltd.

Revision date : 2020-08-27

SDS Library

Move your SDS library online today

Check Icon
Setup – Easy setup with our database of 16 million+ SDSs
Check Icon
Up-to-date – Your SDS get updated to latest versions.
Check Icon
Employee access – Tablets, Smartphones, or link from Corporate Intranet
Check Icon
Safety – One-click access to first aid information.
Check Icon
Labels – Generate Secondary Container Labels with just one click.
Health risk rating 1
Safety risk rating 1
Environmental risk rating 1

General Information

Revision date

2020-08-27

Product name

Desoximetasone Cream USP, 0.25%

Chemical name

Pregna-1, 4-diene-3, 20-dione, 9-fluoro-11, 21-dihydroxy-16- methyl-,(11β,16α)- Molecular Weight: 376.47 g/mol

1.2.1 Relevant identified uses

/ Therapeutic

Emergency telephone

Desoximetasone Cream USP, 0.25% contains the active synthetic corticosteroid desoximetasone, USP. The

Icons in SDS

Company Information

company name

Cadila Healthcare Ltd.

Section 2

SECTION 2: Hazards identification

Dose and Administration Apply a thin film of desoximetasone cream, 0.25% to the affected skin areas twice daily. Rub in gently. Adverse effects The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria. In controlled clinical studies the incidence of adverse reactions was low (0.8%) for desoximetasone cream, 0.25% and included burning, folliculitis, and folliculo-pustular lesions. The incidence of adverse reactions was also 0.8% for desoximetasone cream, 0.05% and included pruritus, erythema, vesiculation, and burning sensation. Over Dose Effect Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects Pregnancy Comments

Teratogenic Effects

Pregnancy Category C Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. Desoximetasone has been shown to be teratogenic and embryotoxic in mice, rats, and rabbits when given by subcutaneous or dermal routes of administration in doses 3 to 30 times the human dose of desoximetasone cream, 0.25% and 15 to 150 times the human dose of desoximetasone cream, 0.05%, or desoximetasone gel, 0.05%. There are no adequate and well-controlled studies in pregnant women on from topically applied corticosteroids. Therefore, desoximetasone cream, 0.25% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time. Nursing Mothers It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman. Pediatric Use Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing’s syndrome than mature patients because of a larger skin surface area to body weight ratio. HPA axis suppression, Cushing’s syndrome, and intracranial hypertension have been reported in pediatric patients receiving topical corticosteroids. Manifestations of adrenal suppression in pediatric patients include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. Administration of topical corticosteroids to pediatric patients should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of pediatric patients.

SDS Library

Move your SDS library online today

Check Icon
Setup – Easy setup with our database of 16 million+ SDSs
Check Icon
Up-to-date – Your SDS get updated to latest versions.
Check Icon
Employee access – Tablets, Smartphones, or link from Corporate Intranet
Check Icon
Safety – One-click access to first aid information.
Check Icon
Labels – Generate Secondary Container Labels with just one click.